51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials
Recommended Citation
Stein-Gold L, Banerjee S, Colombo MJ, Kisa RM, Berger V, Hoyt K, Soung J, Torres T, Bhatia N, Glick BP, Kaufmann MD. 51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials. J Am Acad Dermatol 2024; 91(3):AB31.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Introduction: Deucravacitinib is approved in the US, EU, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib was efficacious and well-tolerated in the global, 52-week, phase 3 POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) trials.[1,2] Methods: Patients were randomized 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. At Week 52, patients could enroll in the POETYK long-term extension (NCT04036435) trial and receive open-label deucravacitinib. Efficacy was evaluated in patients (n=513) who received continuous deucravacitinib from Day 1 of the parent trials for up to 3 years (Week 148), as of the data cutoff (June 15, 2022). Outcomes included mean change from baseline PASI, analyzed using modified baseline observation carried forward, and proportions of patients achieving treat-to-target absolute PASI thresholds. Results: From a mean (SD) baseline PASI score of 21.1 (7.9), improvements were observed beginning at Week 1 (mean change, −3.2 [4.9]) through Week 16 (−15.7 [9.0]), further improved through Week 52 (−17.6 [8.0]), and maintained through Week 148 (−16.4 [8.7]). Proportions of patients achieving 75%-80% reduction from baseline in PASI (75<80), 80<85, 85<90, 90<95, and 95<100, treat-to-target absolute PASI thresholds of ≤1, ≤2, ≤3, ≤4, and ≤5, and absolute PASI of >1 to ≤3 and >3 to ≤5 were increased/maintained from Week 16 through Week 52 and subsequently through Week 148. Conclusion: Efficacy outcomes in PASI scores and at treat-to-target thresholds were clinically meaningful through 3 years of continuous deucravacitinib treatment.
Volume
91
Issue
3
First Page
AB31
